{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:36:25Z","timestamp":1791905785913,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T00:00:00Z","timestamp":1318291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The current situation in the treatment of chronic myeloid leukaemia (CML) presents a new challenge for attempts to measure the therapeutic results, as the CML patients can experience multiple leukaemia-free periods during the course of their treatment. Traditional measures of treatment efficacy such as leukaemia-free survival and cumulative incidence are unable to cope with multiple events in time, e.g. disease remissions or progressions, and as such are inappropriate for the efficacy assessment of the recent CML treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Standard nonparametric statistical methods are used for estimating two principal characteristics of the current CML treatment: the probability of being alive and leukaemia-free in time after CML therapy initiation, denoted as the current cumulative incidence of leukaemia-free patients; and the probability that a patient is alive and in any leukaemia-free period in time after achieving the first leukaemia-free period on the CML treatment, denoted as the current leukaemia-free survival. The validity of the proposed methods is further documented in the data of the Czech CML patients consecutively recorded between July 2003 and July 2009 as well as in simulated data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The results have shown a difference between the estimates of the current cumulative incidence function and the common cumulative incidence of leukaemia-free patients, as well as between the estimates of the current leukaemia-free survival and the common leukaemia-free survival. Regarding the currently available follow-up period, both differences have reached the maximum (12.8% and 20.8%, respectively) at 3 years after the start of follow-up, i.e. after the CML therapy initiation in the former case and after the first achievement of the disease remission in the latter.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Two quantities for the evaluation of the efficacy of current CML therapy that may be estimated with standard nonparametric methods have been proposed in this paper. Both quantities reliably illustrate a patient's disease status in time because they account for the proportion of patients in the second and subsequent disease remissions. Moreover, the model is also applicable in the future, regardless of what the progress in the CML treatment will be and how many treatment options will be available, respectively.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2288-11-140","type":"journal-article","created":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T06:24:46Z","timestamp":1318400686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy"],"prefix":"10.1186","volume":"11","author":[{"given":"Tom\u00e1\u0161","family":"Pavl\u00edk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Janou\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zden\u011bk","family":"Posp\u00ed\u0161il","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Mu\u017e\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"\u017d\u00e1\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zden\u011bk","family":"R\u00e1\u010dil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Klamov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Cetkovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Du\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,11]]},"reference":[{"key":"656_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV: Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med. 2003, 349: 1451-1464. 10.1056\/NEJMra020777.","journal-title":"N Engl J Med"},{"key":"656_CR2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman JM, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006, 108: 1809-1820. 10.1182\/blood-2006-02-005686.","journal-title":"Blood"},{"key":"656_CR3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348: 994-1004. 10.1056\/NEJMoa022457.","journal-title":"N Engl J Med"},{"key":"656_CR4","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D: Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008, 26: 3358-3363. 10.1200\/JCO.2007.15.8154.","journal-title":"J Clin Oncol"},{"key":"656_CR5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, M\u00fcller MC, Ezzeddine R, Countouriotis AM, Kantarjian H: Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008, 22: 1200-1206. 10.1038\/leu.2008.84.","journal-title":"Leukemia"},{"key":"656_CR6","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1002\/cncr.24504","volume":"115","author":"H Kantarjian","year":"2009","unstructured":"Kantarjian H, Pasquini R, L\u00e9vy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009, 115: 4136-4147. 10.1002\/cncr.24504.","journal-title":"Cancer"},{"key":"656_CR7","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007, 110: 3540-3546. 10.1182\/blood-2007-03-080689.","journal-title":"Blood"},{"key":"656_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"58","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 58: 457-481.","journal-title":"J Am Stat Assoc"},{"key":"656_CR9","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007, 26: 2389-2430. 10.1002\/sim.2712.","journal-title":"Stat Med"},{"issue":"Suppl","key":"656_CR10","first-page":"327b","volume":"90","author":"C Craddock","year":"1997","unstructured":"Craddock C, Szydlo R, Olavarria E, Dazzi F, Van Rhee F, Apperley J, Goldman J: Leukaemia free survival after allogeneic transplantation for chronic myeloid leukemia: effect of reclassifying responders to donor lymphocyte infusions as 'currently free of leukemia'. Blood. 1997, 90 (Suppl): 327b-","journal-title":"Blood"},{"key":"656_CR11","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1002\/1097-0258(20001115)19:21<3005::AID-SIM592>3.0.CO;2-9","volume":"19","author":"JP Klein","year":"2000","unstructured":"Klein JP, Szydlo R, Craddock C, Goldman J: Estimation of current leukemia-free survival following donor lymphocyte infusion therapy for patients with leukemia who relapse after allografting: application of a multistate model. Stat Med. 2000, 19: 3005-3016. 10.1002\/1097-0258(20001115)19:21<3005::AID-SIM592>3.0.CO;2-9.","journal-title":"Stat Med"},{"key":"656_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1046\/j.1365-2141.2000.01982.x","volume":"109","author":"JP Klein","year":"2000","unstructured":"Klein JP, Keiding N, Shu Y, Szydlo R, Goldman J: Summary curves for patients transplanted for chronic myeloid leukaemia salvaged by a donor lymphocyte infusion: the current leukaemia-free survival curve. Br J Haematol. 2000, 109: 148-152. 10.1046\/j.1365-2141.2000.01982.x.","journal-title":"Br J Haematol"},{"key":"656_CR13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1080\/01621459.1991.10475108","volume":"86","author":"MS Pepe","year":"1991","unstructured":"Pepe MS: Inference for events with dependent risks in multiple endpoint studies. J Am Stat Assoc. 1991, 86: 770-778. 10.2307\/2290411.","journal-title":"J Am Stat Assoc"},{"key":"656_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/cncr.25604","volume":"117","author":"A Al-Kali","year":"2011","unstructured":"Al-Kali A, Kantarjian H, Shan J, Bassett R, Quint\u00e1s-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J: Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer. 2011, 117: 327-335. 10.1002\/cncr.25604.","journal-title":"Cancer"},{"key":"656_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-4348-9","volume-title":"Statistical Models Based on Counting Processes","author":"PK Andersen","year":"1993","unstructured":"Andersen PK, Borgan \u00d8, Gill RD, Keiding N: Statistical Models Based on Counting Processes. 1993, New York: Springer"},{"key":"656_CR16","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M","volume":"16","author":"DY Lin","year":"1997","unstructured":"Lin DY: Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med. 1997, 16: 901-910. 10.1002\/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M.","journal-title":"Stat Med"},{"key":"656_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01621459.1981.10477650","volume":"76","author":"B Efron","year":"1981","unstructured":"Efron B: Censored Data and the Bootstrap. J Am Stat Assoc. 1981, 76: 312-319. 10.2307\/2287832.","journal-title":"J Am Stat Assoc"},{"key":"656_CR18","unstructured":"Zackova D, Klamova H, Dusek L, Muzik J, Machova Polakova K, Moravcova J, Jurcek T, Dvorakova D, Racil Z, Pospisil Z, Oltova A, Michalova K, Brezinova J, Razga F, Doubek M, Cetkovsky P, Trneny M, Mayer J: Imatinib as the First Line Treatment of Patients with Chronic Myeloid Leukemia Diagnosed in the Chronic Phase: Can We Compare Real Life Data to the Results from Clinical Trials?. Am J Hematol."},{"key":"656_CR19","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet: Chronic myeloid leukemia. An update of concepts and management recommendations of the EuropeanLeukemiaNet. J Clin Oncol. 2009, 27: 6041-6051. 10.1200\/JCO.2009.25.0779.","journal-title":"J Clin Oncol"},{"key":"656_CR20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1541-0420.2006.00529.x","volume":"62","author":"S Datta","year":"2006","unstructured":"Datta S, Sundaram R: Nonparametric estimation of stage occupation probabilities in a multistage model with current status data. Biometrics. 2006, 62: 829-837. 10.1111\/j.1541-0420.2006.00529.x.","journal-title":"Biometrics"},{"key":"656_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0167-7152(01)00155-9","volume":"55","author":"S Datta","year":"2001","unstructured":"Datta S, Satten GA: Validity of the Aalen-Johansen estimators of stage occupation probabilities and Nelson-Aalen estimators of integrated transition hazards for non-Markov models. Stat Probab Lett. 2001, 55: 403-411. 10.1016\/S0167-7152(01)00155-9.","journal-title":"Stat Probab Lett"},{"key":"656_CR22","volume-title":"R: A language and environment for statistical computing","author":"R Development Core Team","year":"2010","unstructured":"R Development Core Team: R: A language and environment for statistical computing. 2010, Vienna, Austria: R Foundation for Statistical Computing, [http:\/\/www.r-project.org\/]"},{"key":"656_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1191\/0962280202sm277ra","volume":"11","author":"JP Klein","year":"2002","unstructured":"Klein JP, Shu Y: Multi-state models for bone marrow transplantation studies. Stat Methods Med Res. 2002, 11: 117-139. 10.1191\/0962280202sm277ra.","journal-title":"Stat Methods Med Res"},{"key":"656_CR24","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","volume":"113","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J: Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009, 113: 6315-6321. 10.1182\/blood-2008-07-166694.","journal-title":"Blood"},{"key":"656_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/0962280208092301","volume":"18","author":"L Meira-Machado","year":"2009","unstructured":"Meira-Machado L, de U\u00f1a-\u00c1lvarez J, Cadarso-Su\u00e1rez C, Andersen PK: Multi-state models for the analysis of time-to-event data. Stat Methods Med Res. 2009, 18: 195-222.","journal-title":"Stat Methods Med Res"},{"key":"656_CR26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.0006-341X.2002.00792.x","volume":"58","author":"S Datta","year":"2002","unstructured":"Datta S, Satten GA: Estimation of Integrated Transition Hazards and Stage Occupation Probabilities for Non-Markov Systems Under Dependent Censoring. Biometrics. 2002, 58: 792-802. 10.1111\/j.0006-341X.2002.00792.x.","journal-title":"Biometrics"},{"key":"656_CR27","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1093\/annonc\/mdq204","volume":"21","author":"JC Soria","year":"2010","unstructured":"Soria JC, Massard C, Le Chevalier T: Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. Ann Oncol. 2010, 21: 2324-2332. 10.1093\/annonc\/mdq204.","journal-title":"Ann Oncol"},{"key":"656_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jnci\/djk091","volume":"99","author":"KS Panageas","year":"2007","unstructured":"Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D: When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2007, 99: 428-432. 10.1093\/jnci\/djk091.","journal-title":"J Natl Cancer Inst"},{"key":"656_CR29","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10985-008-9093-1","volume":"14","author":"L Liu","year":"2008","unstructured":"Liu L, Logan B, Klein JP: Inference for current leukemia free survival. Lifetime Data Anal. 2008, 14: 432-446. 10.1007\/s10985-008-9093-1.","journal-title":"Lifetime Data Anal"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2288-11-140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2288-11-140\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2288-11-140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2288-11-140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T17:07:28Z","timestamp":1630516048000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/1471-2288-11-140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,11]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["656"],"URL":"https:\/\/doi.org\/10.1186\/1471-2288-11-140","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,11]]},"assertion":[{"value":"28 February 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"140"}}